OBJECTIVE: To compare single-session radiofrequency ablation (RFA) and @entity1068 ablation (EA) for treating predominantly cystic thyroid nodules (PCTNs). MATERIALS AND METHODS: This single-blind, randomized trial was approved by the Institutional Review Board of two centers and informed consent was obtained from all @entity1 before enrollment. Fifty @entity1 with a single PCTN (cystic portion less than 90% and greater than 50%) were randomly assigned to be treated by either RFA (25 @entity1 ) or EA (25 @entity1 ) at two hospitals. The primary outcome was the @entity5 volume reduction ratio (%) at the six-month follow-up and the superiority margin was set at 13% (RFA minus EA). Analysis was performed primarily in an intention-to-treat manner. The secondary outcomes were the therapeutic success rate, improvement of symptomatic and cosmetic problems, and the number of major complications. RESULTS: The mean volume reduction was 87.5    11.5% for RFA (n = 22) and 82.4    28.6% for EA (n = 24) (p = 0.710; mean difference [95% confidence interval], 5.1% [-8.0 to 18.2]), indicating no significant difference. Regarding the secondary outcomes, therapeutic success (p = 0.490), mean symptom (p = 0.205) and cosmetic scores (p = 0.710) showed no difference. There were no major complications in either group (p > 0.99). CONCLUSION: The therapeutic efficacy of RFA is not superior to that of EA; therefore, EA might be preferable as the first-line treatment for PCTNs.

Radiofrequency versus XXXX Ablation for Treating Predominantly Cystic Thyroid Nodules: A Randomized Clinical Trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1068 :: ('MESH:D000431', 'Chemical') :: ['ethanol'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor']
@entity1068 :: (MESH:D000431,Chemical) :: ['Ethanol']
